NVO Articles, Novo Nordisk A/S - From 06/24/24

Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart dise...

Gilead Sciences, Inc. (NASDAQ:GILD) witnessed a flurry of Wall Street speculation regarding its potential involvement in the obesity drug market. B...

Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial...

Last month, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss ...

German drug developer Evotec SE (NASDAQ:EVO) is reportedly consulting defense advisers following a significant drop in share price, raising concern...

Eli Lilly & Co. (NYSE:LLY) has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating addition...

Many U.S. parents seeking help for their child with obesity face challenges accessing the recommended treatment. Leading medical groups advocate fo...

Clinical-stage biotech innovator BioRestorative Therapies (NASDAQ:BRTX) recently announced that it is entering a new program of preclinical metabol...

Novo Nordisk (NYSE:NVO) has outperformed the market over the past 10 years by 9.32% on an annualized basis producing an average annual return of 20...

JPMorgan Chase & Co.’s (NYSE:JPM) asset management division has reportedly secured over $500 million for a biotech venture capital fund f...